Progress of Oseltamivir in the Treatment of Influenza A

FAN Hongbo; GUO Jing; LI Junsheng; BIAN Rui; GUO Yinyin

doi:10.14009/j.issn.1672-2124.2021.03.029

您当前的位置：

首页 >

文章列表页 >

Progress of Oseltamivir in the Treatment of Influenza A

更新时间：2022-10-08

- Progress of Oseltamivir in the Treatment of Influenza A
- Vol. 21, Issue 3, Pages: 381-384(2021)
- 作者机构：
  
  1. 天水市中医医院药剂科
  2. 天水市中医医院普外科
  3. 天水市第一人民医院药剂科
  4. 甘肃省临洮县中医医院药剂科
  5. 兰州大学第二医院药学部
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2021.03.029
  CLC： R511.7
- Published：2021，
扫描看全文
[1]樊红波,郭晶,李俊生,边蕊,果茵茵.奥司他韦治疗甲型流感的临床研究进展[J].中国医院用药评价与分析,2021,21(03):381-384.

FAN Hongbo, GUO Jing, LI Junsheng, et al. Progress of Oseltamivir in the Treatment of Influenza A. [J]. 21(3):381-384(2021)
[1]樊红波,郭晶,李俊生,边蕊,果茵茵.奥司他韦治疗甲型流感的临床研究进展[J].中国医院用药评价与分析,2021,21(03):381-384. DOI： 10.14009/j.issn.1672-2124.2021.03.029.

FAN Hongbo, GUO Jing, LI Junsheng, et al. Progress of Oseltamivir in the Treatment of Influenza A. [J]. 21(3):381-384(2021) DOI： 10.14009/j.issn.1672-2124.2021.03.029.

摘要

奥司他韦是目前临床上最常用的抗甲型流感病毒药。但是

世界卫生组织在2017年更新基本药物目录清单时将奥司他韦由核心用药降为辅助用药

并考虑在下一期目录中删除该药。而各国关于流感病毒的最新指南中仍然推荐奥司他韦为一线药物

推荐在发病48 h内尽早应用

且有部分研究推荐重症患者采用大剂量疗法。本文就世界卫生组织及各国指南的不同决策进行相应的文献回顾性分析

分析奥司他韦降级及推荐的循证医学证据

并对重症患者的治疗剂量进行相应探讨。

Abstract

Oseltamivir is one of the most commonly used anti-influenza A virus drugs in clinic.However

when the World Health Organization updated the list of essential medicines in 2017

oseltamivir was adjusted from the core drug to the auxiliary drug

and oseltamivir was considered to be deleted in the next issue of the list.The latest guidelines in various countries still recommended oseltamivir as the first-line drug

and which was recommended to be applied as soon as possible within 48 h after onset

some studies recommended high-dose therapy for patients in severe cases.This paper retrospectively analyzes the relevant literature on the different decisions made by WHO and national guidelines

summarizes the evidence-based medical evidence for the downgrade of oseltamivir and the recommendation of oseltamivir

and discusses the corresponding therapeutic dose for patients in severe cases.

关键词

奥司他韦甲型流感临床进展时间窗剂量选择

Keywords

OseltamivirInfluenza AClinical progressTime windowDosage selection

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Retrospective Analysis of Clinical Characteristics and Whole Process of Integrated Traditional Chinese and Western Medicine Treatment for 20 Patients with COVID-19

Efficacy of Terbutaline Combined with Budesonide Aerosol Inhalation in Prevention of Cough After Influenza A

Related Author

陈灵

柳芳

夏杨

宋红艳

夏敬胜

卢江

陈永刚

LI Wen

Related Institution

Tongren Hospital of Wuhan University

Dept. of Pharmacy, China-Japan Friendship Hospital

Dept. of Military General Medicine Feasured Medical Center of PAP

Brain Center Feasured Medical Center of PAP

Dept. of Geriatrics,Shanghai Fourth Hospital

⁰